Prothena drags WPCT to bottom of performance league table in April The fall in the value of its large investment in Prothena on negative results from two late-stage trials last month had a predictable effect on Woodford Patient Capital (WPCT)’s performance among the biotech-specialist closed end funds this year, although its relative underperformance extends over […]
Trust stalwart Regeneron cuts Praluent price Investment trust stalwart Regeneron Pharmaceuticals (NASDAQ: REGN) and its partner Sanofi yesterday announced a deal with Express Scripts, under which they will substantially lower the net price of Praluent in exchange for exclusive coverage on the US pharmacy benefit manager’s national formulary. The move deals a blow to rival Amgen, […]
OrbiMed-managed trusts benefit from Alexion’s rise Shares in trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) put on 12% last week on the back of a strong financial first quarter with upgraded guidance and positive top-line results from a phase III study of ALXN1210, the company’s longer-acting follow-up to its blockbuster Soliris in the ultra-rate disease of […]
WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]
HBM Healthcare to benefit from Homology Medicines IPO Swiss-listed HBM Healthcare (HBMN) is set to receive a modest boost to its NAV following the US initial public offering last week of Homology Medicines (Nasdaq: FIXX), a US gene editing/gene therapy company developing treatments for rare disease. Homology raised a total of $165.6m from an offering of 10.35m shares at $16.00 […]
Trust favourite Alnylam sees shares tank on competitor success US RNAi therapeutic specialist Alnylam Pharmaceuticals (Nasdaq:ALNY) has seen its shares fall by 22% over the long Easter weekend, principally on news of a surprise positive clinical trial result for a potential competitor to its lead product patisiran, which has been developed initially for hereditary transthyretin-mediated amyloidosis […]
IBT takes profits on Nektar, buys Array SV Health-managed International Biotech Trust (IBT) saw a 2.2% fall in NAV in February, beating the 2.6% decline reported for the sterling-adjusted value of the benchmark Nasdaq biotechnology index by a small margin, one of only a handful of sector specialist trusts to do so. The main positive […]
Trust favourite Alexion notches up a success with important ‘1210 clinical data Alexion (Nasdaq: ALXN) scored an important positive result in the first of two pivotal trials with ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), boosting its shares by around 8% earlier today. ALXN1210 is a long-acting follow-up molecule to Soliris, Alexion’s blockbuster drug for three […]
Swiss trusts top performers among bio sector specialists in Feb – Switzerland’s HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S) were the best performing biotech/pharma specialist investment trusts in February and indeed were the only ones of the 13 monitored by Marten & Co to have recorded any increase in NAV (in sterling terms) in the month. However, […]
Core trust holding Biogen hit by withdrawal of MS drug Core trust holding Biogen is seeing its stock come under further pressure as a result of a decision, announced today with its partner Abbvie, to withdraw for safety reasons the recently-launched multiple sclerosis (MS) treatment Zinbryta. The drug was launched in 2016 for third-line use in MS […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
